HOME >> BIOLOGY >> NEWS
Candidate hookworm vaccine shows benefits in animal study

A paper published in this week's PLoS Medicine shows that vaccination against a protein secreted by the dog hookworm can protect against blood loss and anaemia caused by the same hookworm in dogs. The researchers, led by Alex Loukas and Peter Hotez, showed that vaccination of dogs with recombinant Ac-APR-1, an enzyme that starts the digestion of hemoglobin in hookworms, induced an immune response and resulted in significantly reduced hookworm burdens and fecal egg counts in vaccinated dogs compared to control dogs after challenge with infective larvae of the hookworm Ancylostoma caninum. Most importantly, vaccinated dogs were protected against blood loss and most did not develop anemia, the major result of hookworm disease.

Hookworms are intestinal parasites of mammals, including humans, dogs, and cats; in humans these infections are a leading cause of intestinal blood loss and iron-deficiency anemia. Hookworm infections occur mostly in tropical and subtropical climates and are estimated to infect about 1 billion people worldwide-- about one-fifth of the world's population. People who have direct contact with soil that contains human feces in areas where hookworm is common are at high risk of infection; because children play in dirt, they are at the highest risk.

These results set the stage for the next stage of vaccine development in humans. Loukas and colleagues suggest that the ideal hookworm vaccine would be a mixture of two recombinant proteins, targeting both the infective larva and the blood-feeding adult stage (as targeted here) of the parasite. Such a vaccine would limit the amount of blood loss caused by feeding worms and maintain normal levels of hemoglobin.


'"/>

Contact: Paul Ocampo
press@plos.org
415-624-1224
Public Library of Science
3-Oct-2005


Page: 1

Related biology news :

1. Candidate research sites selected for the National Ecological Observatory Network
2. Designed peptides: Candidates for the treatment of cancer, sexual dysfunction, eating disorders
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
5. Handicapping tuberculosis may be the way to a better vaccine
6. Developing a more effective vaccine for tuberculosis
7. New target for HIV/AIDS drugs and vaccine discovered
8. Genomic analysis uncovers new targets for HIV vaccine
9. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
10. Universal flu vaccine being tested on humans
11. From clinical cancer research: rethinking therapeutic cancer vaccine trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
(Date:12/6/2016)... , ... December 06, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
(Date:12/6/2016)... 6, 2016  SRI International has been awarded ... the National Institutes of Health,s National Institute of ... AIDS (NIAID-DAIDS) to support the manufacturing and characterization ... agents. Under the seven-year contract, SRI will provide ... for candidate HIV-prevention products that emerge from investigator-initiated ...
(Date:12/5/2016)... Axovant Sciences Ltd. (NYSE: AXON ... treatment of dementia, today announced that data on the ... disease will be presented at the 2016 Clinical Trials ... 2016 in San Diego . Intepirdine ... and complex measures of activities of daily living (ADLs) ...
Breaking Biology Technology:
Cached News: